Nicholas Saraceno, Editor

The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.

In this part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, discusses the impact technology has in relation to patients sticking to their medication plan.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence.

The Silverpod MAX RE offers real-time shipment visibility, while also helping companies accomplish their sustainability goals.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

The CDMO will also be adding new equipment for the manufacture of oligonucleotides and peptides.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In the final portion of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the value in needle-to-needle and precision logistics, including its impact over the course of the next five years.

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the development of frozen/cold biologics when it comes to the logistics space, along with how the companies themselves have changed over the years.

The climb is headlined by a 14.1% increase in total demand, according to the IATA.

Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The agreement focuses on augmenting the patient support experience, including from an adherence perspective.

The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.

A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.

The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.

The acquisition provides Ardian with greater insight into the life science industry.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

The San Antonio facility will be taking this biomanufacturing initiative by the end of Q3 2024.

The deal exponentially grows the CDMO’s biopharma capabilities.

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, dives into efficiencies presented by at-home diagnostic tests.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, discusses findings of a new physician survey that the company conducted.

The agreement revolves around providing and maintaining supply chain transparency.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.